# BPC-157 Research References: PubMed, DOI, and FDA Sources — Medicine BPC-157

> BPC-157 references: every study and FDA source cited on this site, with PMIDs, DOIs, and links. The Achilles, angiogenesis, PK, gastric-ulcer, and human-pilot record.

The studies and FDA documents behind every number on this site, each with its PMID, DOI, or URL. Open them and check us.

## BPC-157 research references

Every claim on this site maps to one of the entries below. The preclinical core runs from the foundational rat tendon and gastric-ulcer studies through the 2017 VEGFR2 angiogenesis mechanism and the 2022 pharmacokinetic characterization; the human record is the three small pilots; and the regulatory facts are drawn from the FDA's own compounding pages. Numbers in brackets throughout the site correspond to the numbered list rendered here. Nothing on this page is a recommendation to obtain or administer BPC-157 — it is a reading list for the research record, and it is sold by no one.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[3] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[4] Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. https://pubmed.ncbi.nlm.nih.gov/15052688/
[5] Novinscak T, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-725. https://pubmed.ncbi.nlm.nih.gov/18668315/
[6] Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022;10(12):3221. https://pubmed.ncbi.nlm.nih.gov/36551977/
[7] Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. https://pubmed.ncbi.nlm.nih.gov/34324435/
[8] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. (Human-data context throughout; concludes BPC-157 is investigational with only three small human pilots.) See also Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025 (PMID 40131143); and Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024 (PMID 39325560). https://pubmed.ncbi.nlm.nih.gov/40789979/
[9] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. (Lists BPC-157, KPV, TB-500, and MOTs-C as bulk drug substances being considered for inclusion on the 503A Bulks List; a scheduled discussion, not a decision.) https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
[10] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the bulks-list and PCAC framework; the January 7, 2025 change to categorizing newly nominated substances.) https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[11] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for 'BPC-157 (free base)' and 'BPC-157 acetate'; FDA's stated safety rationale; effective with the September 29, 2023 update.) https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[12] U.S. Food and Drug Administration. Human Drug Compounding — sections 503A and 503B framework and the lawful access pathway (licensed-prescriber evaluation, valid patient-specific prescription, 503A compounding pharmacy or 503B outsourcing facility; ingredient-eligibility requirement; telehealth as a front-end consultation channel only). https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

---

A loud noticeboard for the BPC-157 record — every rat study stamped to its source, every human-data gap and the FDA 503A status posted in plain neon, with no clinic behind the board and nothing here dispensed or sold.